medigraphic.com
ISSN 0016-3813 (Print)

2004, Number S2

<< Back Next >>

Gac Med Mex 2004; 140 (S2)

Obesity and Steatohepatitis. Histological aspects

Pichardo-Bahena R, Paz-Gómez FJ, Estrada-Villaseñor EG

Language: Spanish
References: 43
Page: 33-40
PDF size: 838.85 Kb.


ABSTRACT

The traditional concept of adipose tissue as a passive reservoir for energy storage is no longer valid because it has been demonstrated that adipose tissue is a complex, essential, and highly active metabolic and endocrine organ that not only responds to afferent signals from traditional hormone systems and the central nervous system (CNS), but also expresses and secretes factors with important endocrine functions. These factors include leptin and other cytokines. Adipose tissue is also a major site for metabolism of sex steroids and glucocorticoids. The important endocrine function of adipose tissue is emphasized by adverse metabolic consequences of both adipose tissue excess and deficiency. Adipose tissue excess, particularly in visceral compartment, is associated with insulin resistance, hyperglycemia, dyslipidemia, hypertension, and prothrombotic and proinflammatory states. Liver is one of the principal targets of lipid-associated damage by mechanisms that involve apoptosis activation by source of tumoral necrosis factora and caspase activation and liberation of oxygen-reactive species by oxidative stress and enzymatic chains such as P450, CYP2E1, and CYP3A4, resulting in a continuum involving non alcohol-related fatty liver, non-alcoholic steatohepatitis with or without fibrosis, and liver cirrhosis. This work presents an overview of endocrine functions of adipose tissue and its influence on mechanisms of liver damage.


REFERENCES

  1. Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 1989;320:1060-8.

  2. Donahoo WT, Jenses DR, Shepard TY, Eckel RH. Seasonal variation in lipoprotein lipase and plasma lipids in physically active, normal weight humans. J Clin Endocrinol Metab 2000;85:3065-8.

  3. Lafontan M, Berlan M. Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res 1993;34:1057-61.

  4. Kissebah AH, Alfarsi S, Adams PW, Wynn V. Role of insulin resistance in adipose tissue and liver in the pathogenesis of endogenous hypertriglyceridaemia in man. Diabetologia 1976;12:563-71.

  5. Linda RN, Serdar EB. Estrogen production and action. J Acad Dermatol 2001;45:S116-S124.

  6. Lonn L, Kvist H, Ernest I, Sjostrom L. Changes in body composition and adipose tissue distribution after treatment of women with Cushing’s syndrome. Metabolism 1994;43:1517- 22.

  7. Bengtsson B-A, Eden S, Lonn L. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993;76:309-17.

  8. Johannsson G, Marin P, Lonn L. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism and reduces diastolic blood pressure. J Clin Endocrinol Metab 1997;82:727-34.

  9. Bjorntorp P. Visceral obesity: a “civilization syndrome”. Obesity Res 1993;1:206-22.

  10. Divertie GD, Jensen MD, Miles JM. Stimulation of lipolysis in humans by physiological hypercortisolemia. Diabetes 1991;40:1228-32.

  11. Reynisdottir S, Wahrenberg H, Bylin G, Arner P. Effect of glucocorticosteroid treatment on beta-adrenoceptor subtype function in adipocytes from patients with asthma. Clin Sci 1993;85:237-44.

  12. Horber FF, Marsh HM, Haymond MW. Differential effects of prednisone and growth hormone on fuel metabolism and insulin antagonism in humans. Diabetes 1991;40:141-9.

  13. Johannsson G, Marin P, Lonn L. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism and reduces diastolic blood pressure. J Clin Endocrinol Metab 1997;82:727-34.

  14. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. J Clin Invest 1983;72:1150-62.

  15. Trayhurn P, Beattie, JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001;60:329-9.

  16. Considine RV, Caro JF. Pleotropic cellular effects of leptin. Curr Opin Endocrinol Diabetes 1999;6:163-9.

  17. Marshall S, Garvey WT, Traxinger RR. New insights into the metabolic regulation of insulin action and insulin resistance: role of glucose and amino acids. FASEB J 1991;5:3031-6.

  18. Wang J, Liu R, Hawkins M, Barzilai N, Rossetti L. A nutrientsensing pathway regulates leptin gene expression in muscle and fat. Nature 1998,;393:684-8.

  19. Saad MF, Khan A, Sharma A. Physiological insulinemia acutely modulates plasma leptin. Diabetes 1998;47:544-9.

  20. Utriainen T, Malmstrom R, Makimattila S, Yki-Jarvinen H. Supraphysiological hyperinsulinemia increases plasma leptin concentrations after 4 h in normal subjects. Diabetes 1996;45:1364-6.

  21. Boden G, Chen X, Mozzoli M, Ryan I. Effect of fasting on serum leptin in normal human subjects. J Clin Endocrinol Metab 1996;81:3419-23.

  22. McClain DA, Crook ED. Hexosamines and insulin resistance. Diabetes 1996;45:1003-9.

  23. McClain DA, Alexander T, Cooksey RC, Considine RV. Hexosamines stimulate leptin production in transgenic mice. Endocrinology 2000;141:1999-2002.

  24. Jensen MD, Haymond MW, Gerich JE, Cryer PE, Miles JM. Lipolysis during fasting. Decreased suppression by insulin and increased stimulation by epinephrine. J Clin Invest 1987;79:207-213.

  25. Petruschke TH, Hauner H. Tumor necrosis factor-alpha prevents the differentiation of human adipocyte precursor cells and causes delipidation of newly developed fat cells. J Clin Endocrinol Metab 1993;76:742-7.

  26. Prins JB, Niesler CU, Winterford CM, et al. Tumor necrosis factor-alpha induces apoptosis of human adipose cells. Diabetes 1997;46:1939-44.

  27. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.

  28. Spiegelman BM, Hotamisligil GS. Through thick and thin: wasting, obesity, and TNFalpha. Cell 1993;73:625-7.

  29. Escher G, Galli I, Vishwnanth BS, Frey BM, Frey FJ. Tumor necrosis factor alpha and interleukin 1beta enhance the cortison/cortisol shuttle. J Exp Med 1997;186:189-98.

  30. Thornberry NA, Bull HG, Calacay JR. A novel heterodimeric cycteine protease is required for interleukin-1beta processing in monocytes. Nature 1992;356:768-74.

  31. Wang L, Miura M, Bergeron B, Hzu H, Yuan J. Ich-1, an Ice/ced-3-related gene encodes both positive and negative regulators of programmed cell death. Cell 1994;78:739-750.

  32. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. J Clin Invest 1991;88:1346-53.

  33. Schneider DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 1993;42:1-7.

  34. Bloomgarden Z. Obesity, hypertension, and insulin resistance. Diabetes Care 2002;25:2088-3007.

  35. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease. Diabetes 2001;50:1844-50.

  36. Falchuk KR, Fiske SC, Haggitt RC, Federman R, Trey C. Percentile hepatic fibrosis and intracellular hyalin in diabetes mellitus. Gastroenterology 1980;78:535-41.

  37. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997;126:137-45.

  38. Brunt EM, Janney CJ, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. Am J Gastroenterol 1999;94:2467-74.

  39. Clark J, Diehl AM. Nonalcoholic fatty liver disease an underrecognized cause of cryptogenic cirrhosis. JAMA 2003;289:3000-4.

  40. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 2002;50:585-8.

  41. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis 2001;21:57-69.

  42. Leclercq IA, Farrell GC, Field J, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J Clin Invest 2000;105:1067-75.

  43. Tilg H, Dhiel AM. Mechanisms of disease: cytokines in alcoholic and non-alcoholic steatohepatitis. N Engl J Med 2000;343:1467-76.




2020     |     www.medigraphic.com